X‑Chem Wins 2024 Drug Discovery Chemistry Best of Show Award
X-Chem’s “DELability” offering is recognized as an exceptional innovation
X-Chem has been named the winner of the Best of Show Awards at the 2024 Drug Discovery Chemistry conference, which took place in San Diego in April 2024. The company’s offering, “DELability,” stood out among 13 other finalists.
The conference, attended by more than 900 participants working in pharma, biotech and academia worldwide, focuses on the discovery and optimization challenges of small molecules. As part of the conference, the Best of Show Award is an opportunity for the community to identify exceptionally innovative technologies used by life science professionals. The attendees vote on the most impactful new products.
“This offering has the potential to revolutionize the way scientists evaluate their targets for tractability,” said Anthony Keefe, SVP Innovation at X-Chem. “Our partners can expect a turnaround of results in 30 days. The results will infer if the target of interest is tractable and which targets, if there are multiple, to prioritize for hit identification. For the first time, drug hunters in the field of small molecule discovery can obtain relevant data that provide early assessment of target prior to a full investigational campaign, which can help them significantly de-risk their projects.”
Among the suite of drug discovery solutions X-Chem provides, DELability is differentiated by low investment, fast turnaround time and guaranteed results that can inform next steps. It evaluates targets and reports their suitability for DEL hit identification. This service is especially applicable for clients who have a large portfolio of targets, those who have challenging targets and wish to optimize screening conditions or those who are looking to prioritize constructs for a screen. For more information about DELability, visit https://www.x-chemrx.com/wp-content/uploads/2022/09/X-Chem-DELability-Insert.pdf.